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1. Introduction 
Erythrocyte production is narrow regulatory process. Erythropoiesis starts with 
differentiation of small part of pluripotent stem cells to most primitive erythroid progenitors 
(Colony Forming Units - CFU and Burst Forming Units – BFU). These progenitors are 
developing to erythroid precursors, and follow program of specific differentiation to mature 
erythrocytes. (Suda et al., 1984) Haematopoietic growth factors (interleukin-3, granulocyte-
macrophage factor that stimulate colonies and c-kit ligand) are important for the 
enhancement of progenitor cells, and together with erythropoietin produce large colonies of 
erythroblasts. (Sieff et al., 1986, 1989) Erythropoietin is crucial for finishing the 
differentiation of erythroid progenitors. Erythropoietin also has influence on receptors for 
erythropoietin.  
If renal anaemia is not treated there are: cardiac failure, cerebrovascular ishaemic events, 
lowered cognitive and mental function, tiredness, reactive hypertension, left ventricular 
hypertrophy, increased morbidity and mortality. (Lau et al., 2010; Marti, 2004; Namiuchi et 
al., 2005; Streja et al., 2004) 
2. Anaemia of chronic kidney disease (CKD) - appearance  
Anaemia in CKD in most patients is normochromic and normocytic. It is consequence of 
lower erythropoietin production because of diminished mass of renal parenchyma and 
shorter survival of erythrocytes. Anaemia could appear already at creatinine clearance or 
glomerular filtration rate (GFR) < 35 ml/min/1,73m2. (Levin, 2007; Locatelli et al., 2008)  
In some diseases such as nephronophtysis, medulary cystic disease, endemic or Balkan 
nephropathy, anaemia can be expressed even at creatinine clearance lower than 60 
ml/min/1,73m2. (Locatelli et al., 2009) Studies in children estimated mean appearance of 
anaemia in CKD when GFR is lower than 43 ml/min/1,73m2. (Fadrowski et al., 2008; Yorgin 
et al., 2001) 
2.1 Calculated creatinine clearance from 24 hours urine speciment and estimated GFR 
(e-GFR) 
In children could be used Schwartz (Schwartz-Haycock) formula where from creatinine in 
serum, height and coefficient according to the age and body mass, could be estimated GFR 
without 24 hours specimens (Schwartz et al.; 1984, Schwartz & Gauthier, 1985).  
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                            GFR = k x (height - cm/creatinine in serum - µmol/L)                  (1) 
Measured endogenous creatinine values compared with Schwartz formula showed results 
that anaemia starts at GFR <58 ml/min/1,73m2. It is overestimation when using Schwartz´s 
formula for GFR. (Fadrowski et al., 2008) 
In adult patients for estimation of GFR simple Cockcroft-Gault formula is used. Renal 
function has to be in steady state.  
               GFR=140-age (ys) x lean BW(kg) / creatinine mg/dL x 72 in males  (2) 
During the last years mostly is used MDRD-GFR formula for patients over 18 years of age 
that uses creatinine with more precise method than uncompensated kinetic Jaffe´s method. 
It uses an enzymatic method traceable to the IDMS method and SRM 909b level and is the 
most preferable formula in adults also in Croatia. (Flegar-Mestric et al., 2010)  
The 4-variable equation from the Modificaton  of Diet in Renal Disease (MDRD Study) and 
6-variable MDRD Study were compared with standardized assay of Cockcroft-Gault 
equations , and is found better relation to other measurements of GFR. (Cerriotti et al., 2008; 
Levey et al., 2006) 
Values of new enzymatic method of determination of creatinine are investigated also in 
children and are lower than with Jaffe´s reaction. (Cerriotti et al., 2008) That will bring 
changes in the estimated value for the patients using Schwartz formula with real (lower) 
creatinine in serum and may be better determination of estimated GFR, more similar to 
creatinine clearance in 24 hours urine specimens: MDRD formula can not be used in 
children and still Schwartz formula is actual. 
3. Diagnosis of anaemia 
Important is to evaluated mean values of haemoglobin (Hb) and haematocrit (Htc) in 
normal population according to the age and gender. (Puretic, 2000; Working Party for EBPG, 
1999) In children “normal” values according to the age are presented in Table 1.  
 
Age/gender Hb g/L Htc % 
After birth 165 ± 30 51 ± 9 
1 month 140 ± 40 41 ± 6 
2-6 months 115 ± 25 35 ± 7 
6 mo-2 years 120 ± 15 36 ± 3 
2-6 years 125 ± 10 37 ± 3 
6-12 years 135 ± 20 40 ± 5 
12-18 years/males 145 ± 15 43 ± 6 
12-18 years/females 140 ± 20 41 ± 5 
Table 1. Mean hemoglobin values (Hb)  and haematocrit (Htc) in health population of 
children (X±SD) 
                                                 
1 Legend: k (depending on muscular mass): premature children 1st year = 29, newborns 1st year = 40, 
children and adolescent girls = 48, adolescent boys = 61. Mean in children > 13 years =52 
2 Note: in females GFR is 0,85 of the values in males 
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Diagnosis and treatment of anaemia should start at values of Hb or Htc  <  80% of mean 
values for the age. (Table 2). (Berns, 2008; Puretic, 2009) At adults evaluation of anaemia is 
needed at Hb  < 11o g/L in females and  < 120g/L at males. (Kes & Ljutic, 2008; Locatelli et 
al., 2004; NKF-K/DOQI, 2006, 2007) 
Laboratory diagnostics includes also: Mean Cell (Erythrocyte) Volume - MCV, Mean 
Content of Haemoglobin in Erythrocytes (Mean Cell Haemoglobin – MCH), Mean 
Concentration of Haemoglobin in Erythrocytes  (Mean Cell Haemoglobin Concentration - 
MCHC), reticulocyte number, percentage of hypochromic erythrocytes.  
 
 
Age/gender Hb g/L Htc % 
After birth <130 <41 
1 month <110 <33 
2-6 months <90 <28 
6 mo-2 years <95 <29 
2-6 years <100 <30 
6-12 years <110 <32 
12-18 years/males <115 <35 
12-18 years/females <110 <33 
Adults/males <120 <38 
Adults/ females <110 <33 
 
Table 2. Indications for diagnosis and treatment of anaemia (hemoglobin and haematocrit, 
according to the age, and gender) 
Iron parameters are: iron in serum, total iron bound capacity, ferritin and transferrin 
saturation (TSAT).  
 TSAT (%) = Fe x100/TIBC  (3) 
Further investigations are: occult blood in stool, C- reactive protein as marker of chronic 
inflammation, serum albumin and prealbumin as markers of nutrition.  
Additional laboratory and clinical analysis: vitamin B12 and folic acid levels in plasma, blood 
smear, intact parathormon and parameters of haemolysis (haptoglobin, free haemoglobin, 
methaemalbumin, lactate dehidrogenase, bilirubin, Coomb´s tests, electrophoretic pattern of 
plasma proteins). (Locatelli et al.; 2009)  
In doubt of myelodysplasia bone marrow puncture is needed, and consultation of 
haematologist. In some cases bone biopsy will confirm secondary hyperparathyreoidismus 
or bone marrow fibrosis.When mycrocytic anaemia is present, there is probably iron 
deficiency and not  aluminium intoxication, because reverse osmosis in water treatment is 
used in all dialysis centres , and aluminium based phosphate binders are not more in use. 
Macrocytosis could be associated with folic acid or vitamin B12 deficiency. 
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4. Goals of anaemia treatment 
In anaemia of chronic kidney disease target values for adults are haemoglobin 110-120 g/L. 
For children recommended are values 80% for age Table 2. (Puretic, 2009) 
Values of Hb over 130 mg/L are not recommended because of high risk of heart failure, and 
cerebrovascular events. (Lau et al., 2010; Streja et al., 2004) 
4.1 Significance of iron levels 
Before erythropoietin is included in therapy it is important that serum iron is adequate and 
tissue storages are saturated. Iron therapy has impact on leukocyte surface molecules and 
reactive oxygen species in haemodialysis patients (Guz et al., 2006)  
In the treatment of sideropenia the use of iron sucrose or gluconate and not colloidal forms 
such as dextrin is recommended. (Chertow et al., 2006) Basic parameters for adequate iron 
reserves are: ferritin, transferrin saturation and transferrin. Ferritin initially have to be 
higher than 100 mg/L, TSAT >15% and transferrin in referent values. During maintenance 
of erythropoietin treatment ferritin should be within range 150-300mg/L (not higher than 
400- especially in children and in patients with hepatic lesion). Transferrin saturaton has to 
be 20-40% and transferrin serum level normal.  
At high erythropoietin dosage and ferritin < 100 mg/L) females and diabetics are at higher 
risk of mortality. (Lau et al., 2010) Iron in patients on haemodialysis is administered 
intravenously, and in other intravenously or per os, but intravenous iron administration is 
preferable, also in patients on peritoneal dialysis. (Li & Wang, 2008) In predialysed patients 
better is also the use of intravenous iron (Hoerl, 2008) 
Percentage of hypochromic erythrocytes at start should be usually <10%, and in 
maintenance phase <5%. 
5. Treatment of renal anaemia  
Kidney is the primary organ for erythropoietin production, but at adults small quantity is 
produced also in liver. In the treatment of anaemia androgen drugs are abandoned, and 
erythrocyte transfusions have “time limited” values, and also have complications (Slonim et 
al., 2008; Teruya, 2008). The guidelines for assessing appropriateness of pediatric 
transfusions are introduced (Roseff at al., 2002). The side-effects in potential transmission of 
viruses are well known. (Pampilon et al., 1998)  
Eryhtropoiesis Stimulating Agents (ESA) since 1987 year are present in Croatia. (Gasparovic 
et al., 1990) Its importance (with the first erythropoietin alfa, and later with erythropoietin 
beta, darberythropoietin alfa and continuous erythropoietin receptors activation) dominates 
in the treatment of anaemia in chronic kidney disease and especially in dialysed patients. 
There are experimental studies that erythropoietin attenuates renal injury in acute kidney 
injury. (Spandou et al., 2006) 
Dosage should be individualised, and careful monitoring of erythrocytes, haemoglobin and 
haematocrit is necessary so as continuous correction of other possible factors that influence 
anaemia. 
Minimal investigations before starting erythropoietin therapy are: 1) haemoglobin and 
haematocrit, 2) reticulocytes, 3) mean cell volume (MCV), 4) transferrin saturation (TSAT), 
5) serum ferritin and 6) occult blood in stool. 
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Renal anaemia: in dialysed patients and chronic kidney disease in predialysis patients with 
creatinine clearance < 35 ml/min/1,73m2 or in selected cases <60 ml/min/1,73m2.  (Locatelli 
et al., 2009) In children and adults with chronic renal failure of transplanted kidney, and 
saturated iron reserves, indication is Hb <100 g/L. 
5.2 Administration of erythropoietin  
Subcutaneous administration of alfa or beta erythropoietin have some advantage over 
intravenous, because half-life is 24 hours, and intravenously administered 9 hours. (Besarab 
et al., 2009) In comparison to intravenous administration, during subcutaneous route 
minimal concentrations remain higher over longer time. That implies that erythropoietin 
can be administered in longer periods of time if given subcutaneously. (Portoles at al., 2005) 
Erythropoietin beta could be better metabolically and economically used when applied 
subcutaneously 3x weekly or 1x weekly, even 1 x in two weeks. (Miroescu et al., 2006) 
Darberythropoietin alfa is administered once weekly or once in two weeks, even at four 
weeks. (Carrera et al., 2006; Fang & Chang, 2009) But in patients on haemodialysis 
erythropoietin is given predominantly intravenously in developed countries, because it has 
also local side effects as inflammations, haemorrhage or calciphylaxia, and also has 
historical risk of pure red cell aplasia.  
5.3 Initial dosage 
Erythropoietin alfa  or beta at adults on haemodialysis is administered 1 x 4000 IU/week in 
slow correction ( during 2 - 3 months) or 2 - 3 x 4000 IU/ week in fast correction. Mean dosage 
is mostly 75-100 IU/kg/week. In peritoneal dialysis doses are lower, because in this patients 
haemoglobin could be recovered spontaneously during first 3 months. (Puretic, 2000)  
There are no exact paediatric data in European or USA guidelines for anaemia management 
in chronic kidney disease, but are adult data suggested also for children (75-100 
IU/kg/week).  
In some sporadic reports values for children are higher. In young children: 2 years of age 
initial dosage is 50 U/kg 3x weekly subcutaneously or rarely intravenous. In older children 
dosage is 50-150 IU/kg/week or higher. 
In children, in randomised double blind trial with placebo control in 222 children aged 5-18 
years estimated high dosage in intravenous administration of erythropoietin alfa was  600 
IU/kg/week (not to exceed 40,000) and maximal 900 IU/kg/week ( not to exceed 
60,000U/week). In subcutaneous administration should be used lower dosage. 
(recommendation of the manufacturer) 
With darberythropoietin alfa usual dosage is  0,45 µg/kg BW at adults and children, even at 
children from  age  1 year. (Fang & Chang, 2009; Portoles and al., 2005) 
Continuous erythrocyte receptor activator (C.E.R.A.) administration is nowadays used only 
for patients over 18 years old, but could be used also in postpubertal children. (Carrera et 
al., 2010) 
5.4 Maintenance dosage 
Initial dosage after 4 weeks is titrated and changed according to haemoglobin values: 
a. Lower  dosage for 25% if: 
- target Hb 110-120 is reached  
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- Hb rises  >10 g/L in two weeks 
b. Enlarged dosage for 25% if: 
- Hb  <100 g/L 
- Hb is not rising for 10 g/L after 4 weeks of therapy 
c. not administer erythropoietin for 2-4 weeks if Hb>130 g/L  
The mean dosage of erythropoietin alfa or beta in adults on dialysis in maintenance phase is 
125 IU/kg/week (range 50-250). In children on chronic haemodialysis mean dosage is 175 
IU/kg/week (range 50-450).  On peritoneal dialysis the mean dosage is 75 IU/kg /week 
(range 25-325), in children and adults. 
5.5 Novel Erythropoietin Stimulating Agents - ESA´s 
Darberythropoietin alfa with different aminoacids structure and more sialyc acid could be 
administered at longer intervals: 1x weekly or once in 2 weeks, even 1 x per month and is 
given mostly intravenously 0,45 µg/kg/week. Intravenous half life is 25 hours. Higher 
sialyc acid content, larger molecular weight and negative charge prolonged its half life 3 
times in comparison with erythropoietin alfa and beta. It is usually used once in two weeks. 
(Carrera et al., 2006; Fang & Chang, 2009) 
Last years was developed a novel erythropoietin which is administered once monthly 
(metoxy poliethylen glycol-erythropoietin beta). It reacts on erythropoietin receptors and 
acts as continuous erythropoietin receptor activator (C.E.R.A.), and therefore is quite 
different to other ESA´s.  
Initial dosage is 0,6 µg/kg every two weeks, later could be given 1 x monthly intravenously 
or subcutaneously. (Carrera et al., 2010) 
Erythropoietins are today widely used also in patients with chronic renal failure of grade III 
and IV, and in patients after kidney transplantation with deterioration of graft function, and 
Hb <100 g/L. The use is justified in adults and in children. Conversion between these drugs 






IV or SC dose per week 
Erythropoietin alfa or beta 
(IU) 
IV or SC dose per week 
C.E.R.A. 
(µg) 
IV or SC dose per month 
<40 <8000 120 
40-80 8000-16,000 200 
>80 >16,000 360 
 
Table 3. Suggestions for conversion of different erytropoiesis stimulating agents 
6. Erythtropoietin in surgical treatment of dialysed patients 
If surgical operation is planned in patients with chronic kidney disease erythropoietin could 
be administered 300 IU/kg 10 days before, than the first and fourth postoperative day to 
maintain Hb levels 100-130 g/L. (Locatelli et al., 2008) 
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If patient is on erythropoietin treatment it should not be excluded or diminished. Higher 
dosage of usual erythropoietin dosage has no approval preoperatively, or first week after 
operation.  
7. Erythropoietin in acute medical disorder of dialysed patients 
There are some dilemmas in administration of erythropoietin at acute disorders of organs, 
so as inflammation, pneumonia, cerebrovascular incident, cardiac failure. There are some 
opinions to stop the therapy until recovery, but it will lower haemoglobin later, especially  
in reconvalescent phase, so it has to be maintained at adequate levels of haemoglobin  
110-120 g/L. 
8. Nutritional status in additional treatment of anaemia 
Malnourishment could be expressed in 40-70% in patients on haemodialysis and 30-50% on 
peritoneal dialysis. Anaemia in this group of patient is more severely expressed weather 
receive or not iron and erythropoietin therapy. Anamnesis of dietary nutrients, nutritional 
habits, BMI, exact „dry weight“and anthropometrical measures are important parameters in 
the overall treatment of anaemia. (Furumatsu et al., 2008)  
In children are periodically determined: BW, body hight, head circumference, upper arm 
circumference, cutaneous fold thickness, development and puberty. It is necessary also to 
determine plasma proteins: albumin, prealbumin, transferrin, ferritin, aminoacids and 
cholesterol, urea, creatinine. Ferritin and transferrin are also good parameters of nutrition, 
and not only of anaemia. (Locatelli et al., 2006) 
9. Inadequate response to erythropoietin in anaemia treatment  
9.1 Erythropoietin resistance 
In patients who are dialysed insufficiently or non-adequately (both, haemodyalised and 
peritonealy dialysed patients) resistance to erythropoietin occurs. Resistance to 
erythropoietin treatment is seen also at presence of the chronic inflammatory response  on 
haemodialysis. (Locatelli et al., 2006) The cause could be allergic or toxic reaction to the 
artificial (bioincompatible) membranes and other plastics, or inadequate water treatment – 
endotoxins. Also could appear, but rarely in peritoneal dialysis because of plasticizers or 
endotoxins produced during manufacturing of dialysis solutions - sterile peritonitis. (Geerse 
et al., 2011)  But controversial fact is that erythropoietin therapy acts positively on peritoneal 
mesangial cells and reducing inflammatory response. (Vorobiev et al., 2008)   
The reasons of resistance to erythropoietin could be also subclinical infections, growth 
hormone deficiency, myelodysplastic syndromes, occult malignomas, HIV infection and 
haemoglobinopathias. It has to be excluded malnourishment, bone marrow fibrosis and 
chronic folate and B12 deficiency. (Locatelli et al., 2009) 
9.2 Pure Red Cell Aplasia mediated with antibodies against erythropoietin 
Acquired erythrocite aplasia is very rare disorder of severe anaemia characterized with very 
low reticulocyte count and practically absence of erythrocite precursors in bone marrow. All 
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other strains in bone marrow are normal.  (Fisch et al., 2000; Howman & Kulkarni,2007) 
Some cases are idiopathic, in others could be present disorders as: myelodysplastic 
syndrome, lymphoma, leucemia, autoimmune diseases, thymoma, viral infection 
(Parvovirus B) or drugs (phenitoin, chloramphenicol).  
The incidence of anti erithropoietin antibodies nowadays is signifficantly lower, and 
sporadic cases are verified also with the use of erythropoietin beta and darberythropoietin.  
(Bennett et al., 2007) 
9.3 Pure red cell aplasia – PRCA - not induced with antibodies against erythropoietin 
Numerous reports from 1989- 2004 showed incidence of 1,6/10.000 patients /year  
with rising to 3,43, mostly with high frequency in patients treated with erythropoietin  
alfa- administered subcutaneously. In intravenous administration verified were only 2  
cases or 0,02/10,000 patients/year  which is expected appearance in long term use of  
human recombinant  erythropoietin in population. After change of formulation with change 
of protection with uncoated rubber stopper syringes, and with change of polysorbate  
with human plasma albumin frequency is essentially diminished and is as expected in 
population 0,02/10,000 patients/year. So the reason was of chemical origin. (Boven et al., 
2005) 
10. Erythropoietin in kidney transplantation 
After kidney transplantation anaemia treatment is intriguing and may complicate post 
transplantation course. Early and late posttransplantation anaemia should be differentiated. 
(Choukroun & Martinez, 2005) 
10.1 Early posttransplant anaemia 
Risk factors are: blood loss during or few days after surgery, inflammation, delayed graft 
function and induction therapy with bone marrow suppression. According to some expert 
opinions soon after kidney transplantation in selected patients erythropoietin alfa or beta 
could be used in high dosage up to 125 IU/Kg/every other day IV (up to 400 IU/Kg/week) 
to partially correct anaemia in the first month after transplantation. (Van Biesen at al., 2005) 
Rationale was: prevention of blood transfusions and help in wound healing. In the 
treatment of early anaemia graft function on the other side could be deteriorated. (Gouva et 
al., 2004) It is contraversary to experimental studies (Spandou et al., 2006) Well  known is 
that in good  graft function transplanted kidney  starts with own erythropoietin production 
in 8-30 days, and there is no need for erythropoietin treatment early after transplantation 
according to controlled studies.  
10.2 Late posttransplant anemia 
It appears after 1 month of kidney transplantation, and is mostly seen with chronic allograft 
nephropathy. (Al-Khoury et al., 2006; Baltar et al., 2007) The criteria for the treatment of 
anaemia are the same as in chronic kidney disease of predialysis patients. (Locatelli  et al., 
2009) With deterioration of graft function when GFR is lower than 35 ml/min/1,73m2 and 
Hb lower than 100 g/L could start anaemia treatment with erythropoietin. 
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Drugs  called  erythropoiesis stimulating agents are today widely used in patients with 
chronic renal failure of grade III and IV,  patients on haemodialysis or peritoneal dialysis 
(grade V of chronic renal failure), and in patients after kidney transplantation with 
deterioration of graft function.  Mostly are used in patients with glomerular filtration rate, or 
creatinine clearance below 35 ml/min/1,73m2.. Administration is via intravenous or 
subcutaneous route. Efficacy of subcutaneous administration could be 20-30% higher, but in 
hemodialysed patients is justified intravenous administration. 
After correction of other causes of anaemia dose of erythropoietin stimulating agents 
depends on haemoglobin levels, and the time to achieve recommended haemoglobin levels. 
Their initiation starts when haemoglobin level falls below 8o% of normal values for the age. 
In children older than 6 years erythropoietin therapy starts at haemoglobin  < 100 g/L, or 
haematocrit < 33%.  In adults are introduced when haemoglobin is < 110 g/L, and target 
haemoglobin is between 110-120 g/L.  During maintaining erythropoietin therapy almost 
always iron supplementation  intravenously or peroral is needed. 
After kidney transplantation anaemia can occur and may complicate posttransplantation 
course. According to some opinions soon after kidney transplantation in selected patients 
erythropoietin alfa or beta could be used in high dosage up to 125 U/Kg/every other day 
intravenously.  According to controlled studies in good graft function grafted kidney starts 
with own erythropoietin production in 8-30 days and there is no need for erythropoietin 
treatment. 
For late posttransplant anaemia (after 1st month of kidney transplantation) causes are: poor 
graft function with lack of erythropoietin or erythropoietin resistance, and viral or recurrent 
bacterial infections.  Patients with later poor graft function and chronic anaemia should be 
treated in the same way as other patients with chronic kidney disease. Introducing 
erythropoietin therapy according to good clinical practice of haemoglobin levels and to 
maintain its level as in chronic renal failure before transplantation. 
Advantages of the use of erythropoietins are multiple: there is no need for erythrocyte 
transfusions, and therefore lowered risk for developing of panel reacting antibodies (PRA) 
or HLA antibodies and transfusion transmitted viruses. Transfusions of blood have to be 
used only with low leucocytes protocols (e.g. filtered blood) to diminish load of transfusion 
transmitted viruses (HBV, HCV, CMV, EBV, HIV, TTV) and to lower possible later 
immunological reaction. 
Routine administration of transfusions in patients with chronic kidney diseases is at 
haemoglobin level < 65-60 g/L, except in surgical needs, or in cardyomyopathic patients.  
With recommended haemoglobin levels there is improvement of cardiovascular system, less 
complications including left ventricular hypertrophy, ischemic heart disease, chronic heart 
failure, generalised atherosclerosis and stroke. Better is growth and development of child 
with chronic kidney disease, so as better physical and mental activity and sense of well-
being.  
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